Johnson & Johnson Stock Forecast for 2023 - 2025 - 2030

Updated on 02/01/2023

Stock Rating
11
Price Target
$180.50
Consensus
Outperform
Upside
10.45%
Analysts
6
Stock Rating
11
Upside
10.45%
Analysts
6
Price Target
$180.50

Johnson & Johnson Stock Forecast and Price Target

Johnson & Johnson's most recent price target of $180.50 for 2023 was provided by six renowned analysts over the past few months, with an average prediction of $180.50. If this prediction is correct, Johnson & Johnson's stock could rise by 10.45 percent from its current trading price. The potential increase for the stock is $180.50 per share, with a possible range of $164.00 to $215.00. Even if you are not interested in JNJ stock, you should still be aware of its competitors.

$180.50

10.45% Upside

Outperform
Outperform

Johnson & Johnson Fair Value Forecast for 2023 - 2025 - 2030

Johnson & Johnson's Price has decreased In the last four years, from $145.28 to $121.83 – a 16.14% drop. In the next year, analysts predict that Fair Value will reach $193.94 – an increase of 59.18%. For the next eight years, the forecast is for Fair Value to grow by 89.50%.

2023 Fair Value Forecast
$193.94
2024 Fair Value Forecast
$202.82
2025 Fair Value Forecast
$214.54
2026 Fair Value Forecast
$211.34
2027 Fair Value Forecast
$210.99
2028 Fair Value Forecast
$217.03
2029 Fair Value Forecast
$220.93
2030 Fair Value Forecast
$230.88
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
LLY Stock Forecast Eli Lilly and Outperform 16
$344.15 $333.19 16.23%
PFE Stock Forecast Pfizer Inc Outperform 3
$44.16 $53.97 19.23%
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 16
$323.10 $323.74 0.90%
ZTS Stock Forecast Zoetis Buy 18
$165.49 $207.87 23.87%
ALNY Stock Forecast Alnylam Pharmaceuticals Outperform 7
$226.40 $244.18 10.87%

Johnson & Johnson Revenue Forecast for 2023 - 2025 - 2030

Johnson & Johnson's Revenue has grown in the last four years, jumping from $81.58B to $94.94B – an increase of 16.38%. In the next year, analysts predict that Revenue will reach $100.28B – an increase of 5.62%. For the next eight years, the forecast is for Revenue to grow by 10.90%.

2023 Rev Forecast
$100.28B
2024 Rev Forecast
$103.17B
2025 Rev Forecast
$106.86B
2026 Rev Forecast
$105.05B
2027 Rev Forecast
$105.72B
2028 Rev Forecast
$103.67B
2029 Rev Forecast
$103.65B
2030 Rev Forecast
$105.29B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BAX Stock Forecast Baxter International Outperform 17
$45.69 $62.83 26.94%
VTRS Stock Forecast Viatris Outperform 8
$12.15 $13.70 11.11%
UTHR Stock Forecast United Therapeutics Outperform 12
$263.17 $279.92 12.09%

Johnson & Johnson Dividend per Share Forecast for 2023 - 2025 - 2030

In the last four years, Johnson & Johnson's Dividend per Share has increased by 27.68%, going from $3.54 to $4.52. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach $4.63 – an increase of 2.43%. The Johnson & Johnson forecast is for Dividend per Share to reach $5.75 or grow by 27.21%.

2023 DPS Forecast
$4.63
2024 DPS Forecast
$4.85
2025 DPS Forecast
$5.15
2026 DPS Forecast
$5.27
2027 DPS Forecast
$5.34
2028 DPS Forecast
$5.41
2029 DPS Forecast
$5.51
2030 DPS Forecast
$5.75
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
CTLT Stock Forecast Catalent Outperform 15
$53.55 $76.00 36.32%
IONS Stock Forecast Ionis Pharmaceuticals Outperform 9
$39.87 $52.42 25.41%
CYTK Stock Forecast Cytokinetics Outperform 10
$42.45 $62.07 41.34%

Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B – a 8.28% decrease. In the next year, analysts expect Free Cash Flow to reach $26.97B – an increase of 58.68%. For the next eight years, the forecast is for Free Cash Flow to grow by 71.64%.

2023 FCF Forecast
$26.97B
2024 FCF Forecast
$28.05B
2025 FCF Forecast
$26.74B
2026 FCF Forecast
$26.55B
2027 FCF Forecast
$26.03B
2028 FCF Forecast
$25.74B
2029 FCF Forecast
$28.81B
2030 FCF Forecast
$29.17B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$130.63 $163.67 25.55%
NEOG Stock Forecast Neogen Hold 16
$21.42 $37.00 19.05%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$22.86 $0.00 29.05%

Johnson & Johnson Net Income Forecast for 2023 - 2025 - 2030

In the last four years, Johnson & Johnson's Net Income has grown, increasing from $15.30B to $17.94B – an increase of 17.28%. For next year, the 17 analysts predict Net Income of $28.77B, which would mean an increase of 60.37%. Over the next eight years, the pros' prediction is Net Incomeof $29.27B, which would mean a eight-year growth forecast of 63.15%.

2023 NI Forecast
$28.77B
2024 NI Forecast
$29.94B
2025 NI Forecast
$31.14B
2026 NI Forecast
$30.18B
2027 NI Forecast
$29.48B
2028 NI Forecast
$28.65B
2029 NI Forecast
$28.58B
2030 NI Forecast
$29.27B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
INDV Stock Forecast Indivior PLC Buy 14
£182.10 £3.79 -97.40%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$39.25 $79.67 98.73%
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$30.25 $41.00 45.45%

Johnson & Johnson EBITDA Forecast for 2023 - 2025 - 2030

In the last four years, Johnson & Johnson's EBITDA has decreased from $28.10B to $24.02B – a 14.52% drop. The next year looks promising for Johnson & Johnson, with analysts predicting EBITDA of $36.70B – an increase of 52.76%. Over the next eight years, experts anticipate that Johnson & Johnson's EBITDA will grow at a rate of 63.85%.

2023 EBITDA Forecast
$36.70B
2024 EBITDA Forecast
$38.51B
2025 EBITDA Forecast
$41.20B
2026 EBITDA Forecast
$39.27B
2027 EBITDA Forecast
$38.45B
2028 EBITDA Forecast
$38.52B
2029 EBITDA Forecast
$39.40B
2030 EBITDA Forecast
$39.36B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$11.52 $12.60 8.51%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$41.02 $35.50 -17.11%
LGND Stock Forecast Ligand Pharmaceuticals Outperform 14
$69.70 $195.43 127.40%

Johnson & Johnson EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Johnson & Johnson's EBIT has grown by 19.23%, from $21.18B to $25.25B. For the next year, analysts are expecting EBIT to reach $33.15B – an increase of 31.29%. Over the next eight years, experts predict that EBIT will grow by 68.35%.

2023 EBIT Forecast
$33.15B
2024 EBIT Forecast
$34.55B
2025 EBIT Forecast
$34.38B
2026 EBIT Forecast
$34.46B
2027 EBIT Forecast
$34.67B
2028 EBIT Forecast
$33.90B
2029 EBIT Forecast
$40.90B
2030 EBIT Forecast
$42.50B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$288.07 $170.08 -39.25%
USNA Stock Forecast USANA Health Sciences Hold 14
$58.44 $104.00 -2.46%
NasdaqCM:ARPO Stock Forecast Aerpio Pharmaceuticals - 6
$27.92 $0.00 10.35%

Johnson & Johnson EPS Price Prediction Forecast for 2023 - 2025 - 2030

Johnson & Johnson's EPS has decreased In the last four years, from $8.18 to $6.86 – a 16.14% drop. In the next year, analysts predict that EPS will reach $10.92 – an increase of 59.18%. For the next eight years, the forecast is for EPS to grow by 89.50%.

2023 EPS Forecast
$10.92
2024 EPS Forecast
$11.42
2025 EPS Forecast
$12.08
2026 EPS Forecast
$11.90
2027 EPS Forecast
$11.88
2028 EPS Forecast
$12.22
2029 EPS Forecast
$12.44
2030 EPS Forecast
$13.00
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
CPRX Stock Forecast Catalyst Pharmaceuticals Outperform 16
$15.49 $10.95 -22.53%
TGTX Stock Forecast TG Therapeutics Outperform 9
$15.23 $73.38 24.75%
INVA Stock Forecast Innoviva Hold 16
$12.65 $10.00 26.48%